The promise and challenges of allogeneic and autologous cell therapy

Peering into the cell nucleus. The speckles that contain RNA-processing proteins (red), which lie next to chromosomes (blue). [Credit: Steve Mabon, Tom Misteli, NCI Center for Cancer Research, National Cancer Institute, National Institutes of Health]

Novel cell and gene therapy development continues to expand. Six FDA-approved autologous chimeric antigen receptor T-cell (CAR-T) therapies are on the market in the U.S., all for treating hematologic malignancies, including B-cell acute lymphoblastic leukemia, B-cell non-Hodgkin lymphoma, multiple myeloma, follicular lymphoma, and mantle cell lymphoma.1,2

However, allogeneic cell and gene therapy development has started outpacing autologous development over the past year.3 Allogeneic approaches provide hope to solve common challenges associated with currently approved autologous treatments, including the high cost, complex supply chain, and heterogeneity in manufact…

Read more
  • 0